Adults prescribed verapamil for high blood pressure, angina, or selected heart-rhythm disorders may receive Calan tablets as part of a monitored treatment plan. Calan contains verapamil, a calcium-channel blocker that relaxes blood vessels and slows electrical conduction through the heart.
Calan is an oral tablet medicine containing verapamil. It belongs to the non-dihydropyridine calcium-channel blocker class and is used for selected cardiovascular conditions.
Calan tablets contain verapamil, a non-dihydropyridine calcium-channel blocker. Verapamil reduces the movement of calcium into heart muscle and the muscle lining blood vessels. This lowers the force and rate of cardiac contraction, relaxes arteries, and slows conduction through the atrioventricular node.
The medicine is prescribed for conditions such as:
Calan is taken by mouth as tablets. Different tablet strengths and release characteristics can require different schedules, so there is no single amount suitable for every patient.
A practical detail matters here: verapamil can slow the pulse enough to cause dizziness or unusual fatigue, especially after treatment begins or after the dose increases. A pulse that becomes markedly slower than usual, fainting, or new breathlessness requires prompt medical attention.
Medsafe regulates medicines in New Zealand, while the European Medicines Agency and other regulators describe verapamil as a cardiovascular medicine requiring attention to heart rhythm, blood pressure, and drug interactions [1].
The medicine is prescribed for conditions such as:
The appropriate Calan dose depends on the tablet strength, formulation, reason for treatment, age, response, and liver or kidney function. The prescriber selects the schedule rather than using one standard amount for every patient.
Use the tablets as follows:
Some Calan formulations are designed for modified release. Crushing, chewing, or splitting a modified-release tablet can change how verapamil enters the bloodstream and may increase adverse effects. The correct handling depends on the specific formulation prescribed.
Patients with liver disease may need a lower dose because verapamil is extensively processed by the liver. Older adults may also be more sensitive to low blood pressure, constipation, slowed pulse, and conduction changes.
Alcohol can add to dizziness and low blood pressure. Driving, climbing ladders, and operating machinery deserve extra caution until the individual response is clear.
Calan may be unsuitable for people with specific cardiac conditions. It should not be used in some patients with:
Pregnancy, breastfeeding, liver disease, kidney disease, muscular dystrophy, and a history of heart rhythm problems require a specific prescribing assessment. Dental treatment should also be planned with awareness that long-term verapamil may rarely contribute to gum overgrowth.
The most important interaction groups include:
NOT for you if: you have severe bradycardia, advanced heart block without a pacemaker, cardiogenic shock, or a specialist-identified risk that verapamil could worsen your condition. Discuss alternatives with the prescriber.
Common effects linked with verapamil include constipation, dizziness, headache, nausea, tiredness, flushing, and low blood pressure. Constipation is one of the practical complaints patients mention most often, especially after dose escalation.
Other possible effects include:
Constipation may improve with adequate fluid intake, fibre, and regular movement when these measures are appropriate for the person’s medical condition. Severe abdominal pain, persistent vomiting, or inability to pass stool needs medical assessment.
Seek urgent care for fainting, severe breathlessness, chest pain that is new or worsening, confusion, swelling of the face or tongue, or a very slow or irregular heartbeat. These symptoms can indicate a serious cardiovascular or allergic reaction.
Verapamil can raise concentrations of some medicines. Important examples include certain antiarrhythmics, beta blockers, digoxin, ciclosporin, carbamazepine, simvastatin, and medicines affected by CYP3A4 metabolism. Combining verapamil with another medicine that slows the heart can cause excessive bradycardia or atrioventricular block.
Calcium supports contraction in heart muscle and vascular smooth muscle. Verapamil blocks L-type calcium channels, reducing calcium entry into these tissues.
The main effects are:
This mechanism differs from that of dihydropyridine calcium-channel blockers, which act more strongly on blood vessels and usually have less direct effect on atrioventricular conduction. It also differs from beta blockers, which reduce heart rate and cardiac workload mainly by blocking beta-adrenergic stimulation.
Verapamil may be useful when both vascular relaxation and heart-rate control are clinically relevant. The same cardiac effects create limitations. It may worsen slow heart rhythms, conduction problems, low blood pressure, or reduced pumping function in susceptible patients.
Clinical reviews indexed in PubMed describe verapamil’s role in supraventricular tachycardia and hypertension. FDA and NICE guidance also support treatment selection based on the rhythm diagnosis, ventricular function, and concurrent medicines [2].
Several avoidable errors can reduce treatment control or increase adverse effects:
One detail is easy to miss: verapamil can affect the interpretation of symptoms that patients attribute to ageing or poor sleep. New exercise intolerance, breathlessness, or unusual fatigue may reflect excessive cardiac slowing rather than a minor nuisance.
The choice depends on the clinical problem, not only on the blood-pressure reading.
| Treatment approach | Main pharmacological effect | Typical clinical consideration |
|---|---|---|
| Calan, verapamil | Relaxes vessels and slows atrioventricular conduction | Useful when rate control or angina management is relevant; unsuitable for some slow rhythms or reduced cardiac function |
| Dihydropyridine calcium-channel blocker | Primarily relaxes arterial smooth muscle | Often selected when vascular blood-pressure reduction is needed without deliberate slowing of atrioventricular conduction |
| Beta blocker | Reduces sympathetic stimulation, heart rate, and cardiac workload | May suit selected rhythm or angina indications, but can worsen asthma symptoms, fatigue, or slow pulse in susceptible patients |
Verapamil is not interchangeable with another calcium-channel blocker at the same dose. The medicines differ in their effects on the heart, blood vessels, metabolism, and interaction profile.
A physician may choose Calan for rate control in a selected supraventricular rhythm or for angina when slowing the heart is useful. A different class may be preferred when the patient has conduction disease, heart failure with reduced ejection fraction, significant bradycardia, or a high risk of constipation.
In clinical practice, doctors usually assess the reason for treatment before judging whether Calan is working. A lower blood-pressure reading alone does not explain whether the medicine is appropriate, because the same drug may be prescribed for angina or heart-rate control.
A prescriber commonly reviews pulse, blood pressure, dizziness, bowel habits, ankle swelling, electrocardiogram findings, and the full medicines list. Patients with rhythm disorders may need an ECG rather than relying only on a smartwatch pulse reading. The review also considers whether symptoms began after a dose change. It can identify interactions introduced by another clinician. Follow-up timing depends on the indication and the patient’s response.
A medicine review is needed when another clinician adds an antibiotic, antifungal treatment, heart medicine, seizure medicine, or cholesterol-lowering therapy. Verapamil interactions can develop after a new medicine is introduced, even when Calan itself has been stable for months.
Tell the prescriber about slow pulse, fainting, heart block, heart failure, low blood pressure, liver disease, kidney disease, pregnancy, and breastfeeding. Provide a complete list of prescription medicines, over-the-counter treatments, and supplements, especially beta blockers, digoxin, antiarrhythmics, seizure medicines, and cholesterol-lowering therapy. Medsafe's 2025 cardiovascular safety information supports reviewing cardiac history and interactions before verapamil is started or adjusted [3].
Calan may cause dizziness, low blood pressure, blurred vision, tiredness, or slowed reactions, especially after initiation or a dose change. Do not drive, work at height, or operate machinery until you know that your concentration and balance remain reliable. New Zealand medicines guidance from Medsafe (2025) describes these effects as relevant precautions for medicines that influence cardiovascular function, with patient response varying during treatment [4].
Take the missed tablet when remembered unless the next scheduled dose is close. In that situation, skip the missed dose and return to the normal schedule; do not take two doses together. Advice from the WHO's 2003 medication-safety framework supports avoiding compensatory double dosing when a cardiovascular medicine is missed, because an excessive amount may cause low blood pressure or slow the heart [5].
Urgent assessment is needed for fainting, severe breathlessness, new or worsening chest pain, facial or tongue swelling, severe weakness, confusion, or a very slow or irregular heartbeat. Medsafe's 2025 safety guidance notes that these symptoms may signal a serious rhythm problem, severe blood-pressure reduction, worsening cardiac function, or an allergic reaction. Do not take another scheduled dose while seeking urgent advice if a clinician has specifically told you to stop for a serious reaction.
Pregnancy and breastfeeding require an individual assessment before treatment begins or continues. Verapamil crosses the placenta, and small amounts may pass into breast milk, so the prescriber weighs maternal benefit, alternatives, and infant monitoring. The EMA's 2024 product-information guidance for verapamil-based treatment advises discussing pregnancy and lactation directly with the prescribing clinician rather than making an independent change.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Ashburton, took the prescribed dose of Calan for several weeks for a prescribed heart-rate problem: “The racing episodes became less frequent, and I felt calmer during normal activity. Constipation appeared early, so I changed my routine and raised it at my follow-up. The tablets helped, but the bowel side effect was not something I expected.”
Queenstown, used the prescribed Calan dose for blood-pressure control during the first days of treatment: “My readings improved after the dose was adjusted. During the first days I felt light-headed when standing quickly, especially after work. That settled, but I avoided driving until I knew how the tablets affected me.”
Tauranga, received the prescribed Calan dose for a rhythm-related indication for several weeks: “The palpitations were much less noticeable after treatment began. I also had tiredness and a slower pulse, which made exercise feel different. My clinician reviewed the ECG and changed the plan rather than telling me to push through it.”
